Endoscopy 2020; 52(S 01): S37
DOI: 10.1055/s-0040-1704116
ESGE Days 2020 oral presentations
Saturday, April 25, 2020 11:00 – 13:00 Advances in endoluminal endoscopy Liffey Meeting Room 2
© Georg Thieme Verlag KG Stuttgart · New York

OUTCOMES FROM THE UK PURASTAT REGISTRY - A MULTICENTRE PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE THE ROLE OF PURASTAT IN THE MANAGEMENT OF GASTROINTESTINAL BLEEDING (POPS)

S Arndtz
1   Queen Alexandra Hospital, Portsmouth, United Kingdom
,
S Subramaniam
1   Queen Alexandra Hospital, Portsmouth, United Kingdom
,
E Hossain
1   Queen Alexandra Hospital, Portsmouth, United Kingdom
,
M Abdelrahim
1   Queen Alexandra Hospital, Portsmouth, United Kingdom
,
Y Ang
2   Salford Royal NHS Foundation Trust, Salford, United Kingdom
,
I Beintaris
3   North Tees and Hartlepool NHS Foundation Trust, Stockton-on-Tees, United Kingdom
,
M di Pietro
4   Addenbrooke’s Hospital, Cambridge, United Kingdom
,
M Iacucci
5   University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
,
B Saunders
6   St Mark’s Hospital, Harrow, United Kingdom
,
N Suzuki
6   St Mark’s Hospital, Harrow, United Kingdom
,
P Bhandari
1   Queen Alexandra Hospital, Portsmouth, United Kingdom
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
23. April 2020 (online)

 

Aims PuraStat is a novel haemostatic agent without the risk of thermal injury, perforation or loss of mucosal views associated with other treatments such as heat therapy, clips or haemostatic powders. Our aim was to evaluate the efficacy of PuraStat in the prevention and treatment of gastro-intestinal bleeding.

Methods This is a prospective analysis of PuraStat use in the UK, with 6 tertiary referral centres open to recruitment. Data was collected on procedure & lesion details, haemostasis management and complications for endoscopies where PuraStat was used.

Results 226 procedures were included across 3 indications: 198 high risk resection, 6 upper gastro-intestinal bleeding (UGIB) and 22 radiation proctopathy. PuraStat was used for immediate haemostasis in 100 bleeding episodes, of which 92 were as primary agent and 8 as secondary agent (after failure of alternative initial therapy) and for prevention of delayed bleeding in 177 cases (see [Table 1]). PuraStat was additionally used in 22 radiation proctopathy cases, as sole therapy in 14 and secondary therapy in 8, with improvement in patient reported symptom score and haemoglobin. The average volume of Purastat used across all indications was 0.43mls for haemostasis and 2.33mls for prevention of delayed bleeding. No PuraStat related complications were reported.

Tab. 1

Haemostatic efficacy of PuraStat

Indication

Procedures n=204 (n)

Immediate haemostasis n=100 (n, %)

Prevention of delayed bleeding n=177 (n, %)

High risk resection

198

90/98 (91.8%)

169/173 (97.7%)

UGIB

6

2/2 (100%)

4/4 (100%)

Overall

204

92/100 (92.0%)

173/177 (97.7%)

Conclusions Our data shows PuraStat is safe and effective for a range of indications, with most use within high risk resections. It shows high efficacy in both immediate haemostasis and prevention of delayed bleeding. We believe PuraStat is a promising new agent in the prevention and management of gastro-intestinal bleeding.